Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Ayahuasca PTSD Clinical trial

1 paper

Ayahuasca for PTSD

Based on 11 papers

Research on ayahuasca for PTSD is small but interesting. Lab and animal studies show the active ingredient (DMT) can change brain cells and connections. Human studies that directly test ayahuasca for PTSD are limited, so most clinical claims are based on early trials, patient reports, or studies of other psychedelics. Scientists see promise, but they also see important limits. Stronger clinical evidence exists for other psychedelic treatments (for example MDMA) than for ayahuasca. Safety questions, the right way to give the medicine, and whether results apply across different cultures still need more study.

Key findings

  • Some lab and animal studies show DMT (the main active compound in ayahuasca) can make neurons grow more branches and form more synapses, which is a sign the brain’s wiring can change (this is called neuroplasticity). 15050 15091 15059
  • A large review of human studies found no clear change in blood levels of BDNF (a protein often used as a marker of brain change) after people received psychoplastogen drugs, which suggests blood BDNF is not a reliable proof that these drugs changed the human brain. 15129 15091
  • Patient reports collected across studies of several psychedelics (including ayahuasca) often describe helpful experiences such as personal insights, a changed sense of self, and stronger social connection. People also say the therapy setting, music, and the relationship with therapists strongly shape outcomes. 15092 15063
  • Evidence that psychedelic treatments can help PTSD is growing, but most of the strongest clinical trials for PTSD so far have tested MDMA-assisted therapy rather than ayahuasca. Trials of ayahuasca specifically are fewer and smaller. 15063 15085 15059
  • Animal studies and some reviews show effects of compounds can depend on dose and sex, and high doses or certain drugs can cause harm in animals. This means safety and dosing need careful study before saying ayahuasca is safe for PTSD patients. 15050 15085 15091
  • Reviews of the field emphasize that how the drug is given and the surrounding therapy matter a lot for results and safety. Researchers stress careful medical oversight and prepared therapy sessions as part of treatment plans in studies. 15091 15063 15087
  • People of color were greatly underrepresented in older psychedelic-assisted psychotherapy studies, so we cannot be sure results apply equally across different ethnic and cultural groups. 15095 15092
  • Key unknowns remain: we still need larger, well-controlled clinical trials of ayahuasca for PTSD, clearer measures of how it works in the human brain, and longer follow-up to know lasting benefits and risks. 15091 15129 15059

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Jennifer Mitchell, B. Anderson
Neuropsychopharmacology Summary & key facts 2023 44 citations

This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.